Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma
Oral Diseases · 2024
DOI: 10.1111/odi.14897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Than-Thuy Nham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, Service de Chirurgie Maxillo-Faciale et Stomatologie, Nantes, France. Hauptthemen laut MEDLINE: Zoledronic Acid, Osteosarcoma, Bone Density Conservation Agents, Diphosphonates. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centre Hospitalier Universitaire de Nantes, Fondation des Gueules Cassées.
Abstract (Originalsprache)
Objectives
Investigation of the therapeutic effect of zoledronic acid (ZA) in a preclinical model of jaw osteosarcoma (JO). Materials and Methods The effect of 100 μg/kg ZA administered twice a week was assessed in a xenogenic mouse model of JO. The clinical (tumor growth, development of lung metastasis), radiological (bone microarchitecture by micro‐CT analysis), and molecular and immunohistochemical (TRAP, RANK/RANKL, VEGF, and CD146) parameters were investigated.
Results
Animals receiving ZA exhibited an increased tumor volume compared with nontreated animals (71.3 ± 14.3 mm 3 vs. 51.9 ± 19.9 mm 3 at D14, respectively; p = 0.06) as well as increased numbers of lung metastases (mean 4.88 ± 4.45 vs. 0.50 ± 1.07 metastases, respectively; p = 0.02). ZA protected mandibular bone against tumor osteolysis (mean bone volume of 12.81 ± 0.53 mm 3 in the ZA group vs. 11.55 ± 1.18 mm 3 in the control group; p = 0.01). ZA induced a nonsignificant decrease in mRNA expression of the osteoclastic marker TRAP and an increase in RANK/RANKL bone remodeling markers.
Conclusion
The use of bisphosphonates in the therapeutic strategy for JO should be further explored, as should the role of bone resorption in the pathophysiology of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nantes Université, CHU Nantes, Service de Chirurgie Maxillo-Faciale et Stomatologie, Nantes, France.
- Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Nantes, France.
- Nantes Université, Oniris, Univ Angers, CHU Nantes, INSERM, Regenerative Medicine and Skeleton, RMeS, UMR 1229, Nantes, France.
- Cancer Biobank of Toulouse, IUCT Oncopole, Toulouse University Hospital, Toulouse Cedex 9, France.
- Department of Pathology, IUCT Oncopole, Toulouse University Hospital, Toulouse Cedex 9, France.
ORCID-Profile: Hélios Bertin
Förderung
- Centre Hospitalier Universitaire de Nantes
- Fondation des Gueules Cassées
Zitieren
APA
Nham, T. T., Guiho, R., Brion, R., Amiaud, J., Le Royer, B. B., Gomez-Brouchet, A., Rédini, F., & Bertin, H. (2024). Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma. Oral Diseases. https://doi.org/10.1111/odi.14897
Vancouver
Nham TT, Guiho R, Brion R, Amiaud J, Le Royer BB, Gomez-Brouchet A, et al. Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma. Oral Diseases. 2024. doi:10.1111/odi.14897
BibTeX
@article{Nham2024,
author = {Nham, Than-Thuy and Guiho, Romain and Brion, Régis and Amiaud, Jérôme and Le Royer, Bénédicte Brounais and Gomez-Brouchet, Anne and Rédini, Françoise and Bertin, Hélios},
title = {Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14897}
}
EUVIMED